Literature DB >> 19889950

Should the PANSS be rescaled?

Michael Obermeier1, Andreas Mayr, Rebecca Schennach-Wolff, Florian Seemüller, Hans-Jürgen Möller, Michael Riedel.   

Abstract

The design of the Positive and Negative Syndrome Scale (PANSS) with item levels ranging from 1 to 7 leads to the trivial result that the 30-item scale's zero level (no symptoms) is 30. This causes serious problems when ratios are calculated which always implicitly depend on a natural zero point (equals 0). Recent publications concerning efficacy of antipsychotics correctly suggest a subtraction of 30 points to every PANSS before calculating percent change (PC). Nevertheless, the traditional approach using uncorrected scores is still in common practice. This analysis aims to clarify which approach is the most appropriate from a statistical perspective.For analysis, data from a naturalistic study on 400 patients with a schizophrenic spectrum disorder and simulated data sets were used. While calculations concerning absolute score values and their differences are not affected, considerable problems arise in calculations of PC and related response criteria. Even significance levels of estimated treatment effects change, depending on the structure of the data (eg, baseline symptom severity). Using a PANSS version with items ranging from 0 to 6 would avoid such often neglected pitfalls.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19889950      PMCID: PMC2879676          DOI: 10.1093/schbul/sbp124

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  14 in total

1.  Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia.

Authors:  E Spina; A Avenoso; G Facciolà; M Salemi; M G Scordo; M Ancione; A G Madia; E Perucca
Journal:  Psychopharmacology (Berl)       Date:  2001-01-01       Impact factor: 4.530

2.  The positive and negative syndrome scale (PANSS) for schizophrenia.

Authors:  S R Kay; A Fiszbein; L A Opler
Journal:  Schizophr Bull       Date:  1987       Impact factor: 9.306

3.  Retention rates in placebo- and nonplacebo-controlled clinical trials of schizophrenia.

Authors:  A Labelle; L J Boulay; Y D Lapierre
Journal:  Can J Psychiatry       Date:  1999-11       Impact factor: 4.356

4.  A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia.

Authors:  Alan Breier; Karena Meehan; Martin Birkett; Stacy David; Iris Ferchland; Virginia Sutton; Cindy C Taylor; Rebecca Palmer; Martin Dossenbach; Geri Kiesler; Shlomo Brook; Padraig Wright
Journal:  Arch Gen Psychiatry       Date:  2002-05

5.  Risperidone treatment of outpatients with schizophrenia: no evidence of sex differences in treatment response.

Authors:  A Labelle; M Light; F Dunbar
Journal:  Can J Psychiatry       Date:  2001-08       Impact factor: 4.356

6.  Clozapine alone versus clozapine and risperidone with refractory schizophrenia.

Authors:  William G Honer; Allen E Thornton; Eric Y H Chen; Raymond C K Chan; Jessica O Y Wong; Andrea Bergmann; Peter Falkai; Edith Pomarol-Clotet; Peter J McKenna; Emmanuel Stip; Richard Williams; G William MacEwan; Kishor Wasan; Ric Procyshyn
Journal:  N Engl J Med       Date:  2006-02-02       Impact factor: 91.245

7.  Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group.

Authors:  J Peuskens
Journal:  Br J Psychiatry       Date:  1995-06       Impact factor: 9.319

8.  Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.

Authors:  John M Kane; William H Carson; Anutosh R Saha; Robert D McQuade; Gary G Ingenito; Dan L Zimbroff; Mirza W Ali
Journal:  J Clin Psychiatry       Date:  2002-09       Impact factor: 4.384

9.  Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study.

Authors:  Emilio Sacchetti; Alessandro Galluzzo; Paolo Valsecchi; Fabio Romeo; Barbara Gorini; Lewis Warrington
Journal:  Schizophr Res       Date:  2009-03-09       Impact factor: 4.939

10.  Risperidone in the treatment of schizophrenia.

Authors:  S R Marder; R C Meibach
Journal:  Am J Psychiatry       Date:  1994-06       Impact factor: 18.112

View more
  19 in total

1.  Challenging the understanding of significant improvement and outcome in schizophrenia - the concept of reliable and clinically significant change methods.

Authors:  Rebecca Schennach; Hans-Jürgen Möller; Michael Obermeier; Florian Seemüller; Markus Jäger; Max Schmauss; Gerd Laux; Herbert Pfeiffer; Dieter Naber; Lutz G Schmidt; Wolfgang Gaebel; Joachim Klosterkötter; Isabella Heuser; Wolfgang Maier; Matthias R Lemke; Eckart Rüther; Stefan Klingberg; Markus Gastpar; Richard Musil; Ilja Spellmann; Michael Riedel
Journal:  Int J Methods Psychiatr Res       Date:  2015-07-14       Impact factor: 4.035

Review 2.  Oxytocin effects in schizophrenia: Reconciling mixed findings and moving forward.

Authors:  Ellen R Bradley; Joshua D Woolley
Journal:  Neurosci Biobehav Rev       Date:  2017-05-12       Impact factor: 8.989

3.  Converting positive and negative symptom scores between PANSS and SAPS/SANS.

Authors:  Theo G M van Erp; Adrian Preda; Dana Nguyen; Lawrence Faziola; Jessica Turner; Juan Bustillo; Aysenil Belger; Kelvin O Lim; Sarah McEwen; James Voyvodic; Daniel H Mathalon; Judith Ford; Steven G Potkin
Journal:  Schizophr Res       Date:  2013-12-11       Impact factor: 4.939

Review 4.  Is the PANSS used correctly? a systematic review.

Authors:  Michael Obermeier; Rebecca Schennach-Wolff; Sebastian Meyer; Hans-Jürgen Möller; Michael Riedel; Daniela Krause; Florian Seemüller
Journal:  BMC Psychiatry       Date:  2011-07-18       Impact factor: 3.630

5.  How Many Patients With Schizophrenia Do Not Respond to Antipsychotic Drugs in the Short Term? An Analysis Based on Individual Patient Data From Randomized Controlled Trials.

Authors:  Myrto T Samara; Adriani Nikolakopoulou; Georgia Salanti; Stefan Leucht
Journal:  Schizophr Bull       Date:  2019-04-25       Impact factor: 9.306

6.  The GRM7 gene, early response to risperidone, and schizophrenia: a genome-wide association study and a confirmatory pharmacogenetic analysis.

Authors:  E Sacchetti; C Magri; A Minelli; P Valsecchi; M Traversa; S Calza; A Vita; M Gennarelli
Journal:  Pharmacogenomics J       Date:  2016-02-09       Impact factor: 3.550

7.  Presynaptic Dopamine Synthesis Capacity in Schizophrenia and Striatal Blood Flow Change During Antipsychotic Treatment and Medication-Free Conditions.

Authors:  Daniel Paul Eisenberg; Lisa Yankowitz; Angela M Ianni; Dani Y Rubinstein; Philip D Kohn; Catherine E Hegarty; Michael D Gregory; José A Apud; Karen F Berman
Journal:  Neuropsychopharmacology       Date:  2017-04-07       Impact factor: 7.853

8.  How Efficacious Are Antipsychotic Drugs for Schizophrenia? An Interpretation Based on 13 Effect Size Indices.

Authors:  Stefan Leucht; Spyridon Siafis; Rolf R Engel; Johannes Schneider-Thoma; Irene Bighelli; Andrea Cipriani; Toshi A Furukawa; John M Davis
Journal:  Schizophr Bull       Date:  2022-01-21       Impact factor: 7.348

9.  Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia.

Authors:  Haya Ascher-Svanum; Fangyi Zhao; Holland C Detke; Allen W Nyhuis; Anthony H Lawson; Virginia L Stauffer; William Montgomery; Michael M Witte; David P McDonnell
Journal:  BMC Psychiatry       Date:  2011-09-23       Impact factor: 3.630

10.  Temporal Dynamics in Degree Centrality of Brain Functional Connectome in First-Episode Schizophrenia with Different Short-Term Treatment Responses: A Longitudinal Study.

Authors:  Yingchan Wang; Yuchao Jiang; Wenjun Su; Lihua Xu; Yanyan Wei; Yingying Tang; Tianhong Zhang; Xiaochen Tang; Yegang Hu; Huiru Cui; Jinhong Wang; Dezhong Yao; Cheng Luo; Jijun Wang
Journal:  Neuropsychiatr Dis Treat       Date:  2021-05-18       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.